论文部分内容阅读
膦甲酸钠(Foscarnet sodium),商品名Fos-cavir,是由Astra公司开发的一种有效的抗病毒药物,1989年在瑞典上市。作为非核苷类抗病毒药物,膦甲酸钠抑制疱疹病毒的DNA聚合酶,不需预先经病毒TK活化。它作为聚合反应产物焦磷酸盐的类似物,直接作用于核酸聚合酶的焦磷酸结合部位,从而抑制DNA及RNA的合成。膦甲酸钠对病毒酶有很好的亲和力,体外试验表明,它有抗所有的人类疱疹病毒和人类免疫缺陷病毒的活性。在抗无环鸟苷的单纯疱疹病毒治疗方面,膦甲酸钠是一种有希望的药物。该药可能发生的副作用是肾毒性、特征
Foscarnet sodium, a trade name of Fos-cavir, is a potent antiviral drug developed by Astra and was launched in Sweden in 1989. As a non-nucleoside antiviral drug, foscarnet inhibits the herpes virus DNA polymerase without prior activation by viral TK. It acts as an analogue of the pyrophosphate salt of the polymerization reaction and acts directly on the pyrophosphate binding site of the nucleic acid polymerase, thereby inhibiting the synthesis of DNA and RNA. Foscarnet has a good affinity for the viral enzyme and in vitro tests show it has anti-human herpesvirus and human immunodeficiency virus activity. Foscarnet is a promising drug in the herpes simplex virus-resistant treatment of acyclovir. Side effects of this medicine may be nephrotoxicity, characteristics